A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
Clin. transl. oncol. (Print)
; 13(9): 686-691, sept. 2011. tab
Artigo
em Inglês
| IBECS
| ID: ibc-125874
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
INTRODUCTION:
The objective was to evaluate a dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant treatment for patients with locally advanced breast cancer. PATIENTS ANDMETHODS:
Ninety-nine patients were included and received 100 mg/m(2) of docetaxel every two weeks for four cycles followed by 60 mg/m(2) of doxorubicin and 600 mg/m(2) of cyclophosphamide every two weeks for four cycles. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was administered systematically to all patients.RESULTS:
Efficacy and toxicity analyses were carried out on an intention-to-treat basis. After treatment, complete pathological response in the breast and lymph nodes was confirmed in 15 patients (15%, 95% confidence interval [CI] 8.4-22.9). Clinical response rate was 74% (95% CI 65-82), of which 19% were complete responses. Breast-conserving surgery could be performed in 41% of patients. The dose-dense schedule was generally well tolerated. The most important grade 3/4 toxicities per patient were cutaneous toxicity (12.1%) and hepatic dysfunction (9.1%) during docetaxel administration, and neutropenia (28.1%) and leucopenia (8.3%) with AC.CONCLUSION:
A dose-dense schedule of docetaxel followed by AC as neoadjuvant treatment is an effective and safe treatment for locally advanced breast cancer. Primary prophylaxis with G-CSF, and possibly the change in the sequence of drug administration, appears to play a major role in avoiding the excessive toxicity of dose-dense schedule (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Carcinoma Ductal de Mama
/
Ciclofosfamida
/
Taxoides
Tipo de estudo:
Estudo de avaliação
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2011
Tipo de documento:
Artigo
Instituição/País de afiliação:
Centro Oncológico Regional/Spain
/
Complexo Hospitalario Arquitecto Marcide-Novoa Santos/Spain
/
Complexo Hospitalario Universitario A Coruńa/Spain
/
Complexo Hospitalario de Ourense/Spain
/
Hospital Povisa/Spain
/
Hospital Xeral-Calde/Spain
/
Hospital de León/Spain